Compare SY & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SY | PYXS |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 289.0M | 243.5M |
| IPO Year | 2019 | 2021 |
| Metric | SY | PYXS |
|---|---|---|
| Price | $2.91 | $1.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $5.50 | ★ $7.50 |
| AVG Volume (30 Days) | 786.7K | ★ 1.2M |
| Earning Date | 11-17-2025 | 11-03-2025 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $201,132,009.00 | $2,820,000.00 |
| Revenue This Year | $5.27 | N/A |
| Revenue Next Year | $51.30 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.67 | $0.83 |
| 52 Week High | $6.28 | $5.55 |
| Indicator | SY | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 42.74 | 20.88 |
| Support Level | $2.78 | $4.10 |
| Resistance Level | $3.00 | $4.58 |
| Average True Range (ATR) | 0.17 | 0.40 |
| MACD | -0.01 | -0.36 |
| Stochastic Oscillator | 23.64 | 2.07 |
So-Young International Inc is an online destination for discovering, evaluating, and reserving medical aesthetic services in China. Its business model comprises four integrated components: professional content and its distribution through social media networks and its targeted media platforms in China, a social community characterized by signature user-generated content, Online reservation services for a medical aesthetic treatment, and the research, development, production, sales and agency of laser and other optoelectronic medical beauty equipment. It generates revenue from information services fees and reservation services fees from medical aesthetic service providers.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.